Yes, NODDI has shown promise in monitoring the response of brain tumors to treatment modalities such as chemotherapy and radiation therapy. Changes in neurite density and orientation dispersion can indicate how well the tumor is responding to treatment. For example, a decrease in NDI and an increase in ODI may suggest effective tumor shrinkage and reduced cellularity. This information can help clinicians adjust treatment plans in real-time, potentially improving patient outcomes.
